Interleukin-27 and Risk of Coronary Artery Disease | ||||
| Journal of advanced Biomedical and Pharmaceutical Sciences | ||||
| Article 1, Volume 2, Issue 1, January 2019, Page 1-6 PDF (565.29 K) | ||||
| Document Type: Review Articles | ||||
| DOI: 10.21608/jabps.2018.5020.1020 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Mohamed Abu Khesha kamel1; Ahmed Ragaa Nour Ibrahim  2; Gamal El-Din Abu Rahma3
| ||||
| 1Molecular Biology center, Faculty of pharmacy, Minia university ,Minia | ||||
| 2Department of Biochemistry, Faculty of Pharmacy, Minia University, 61519 Minia, Egypt | ||||
| 3Department of Medicinal chemistry, Faculty of Pharmacy, Minia University, 61519 Minia, Egypt | ||||
| Abstract | ||||
| Cardiovascular diseases (CVDs) are the most abundant causative factors of mortality and morbidity in the world specifically in the developing countries. Many studies on humans and animals prove that inflammation plays a key role in the initiation and propagation of the process of atherosclerosis. Interleukin-27 (IL-27) is a new IL-12/IL-6 family member which is a heterodimeric multifunctional pro- and anti-inflammatory cytokine. IL-27 one of the important cytokines distinguished in atherosclerotic plaques. In this review, we demonstrate the coronary artery disease and its pathogenesis, the role of inflammation in the initiation and progression of atherosclerosis, IL-27, IL-27 receptors and signaling pathway, pro and anti-inflammatory characters of IL-27 and finally the effect of IL-27 as an inflammatory mediator in the process of atherogenesis. | ||||
| Keywords | ||||
| Interleukin-27; Coronary Artery Disease; cardiovascular diseases; Inflammation; interleukin | ||||
|
Statistics Article View: 437 PDF Download: 536 |
||||
